Phase i study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma

Journal of Hepatology

Volumn 59, Issue 6, 2013, Pages 1271-1277

  Finn, Richard S ^a   Poon, Ronnie T P ^b   Yau, Thomas ^b   Klümpen, Heinz Josef ^c   Chen, Li Tzong ^d   Kang, Yoon Koo ^e   Kim, Tae You ^f   Gomez Martin, Carlos ^g   Rodriguez Lope, Carlos ^h   Kunz, Tiffany ⁱ   Paquet, Thierry ⁱ   Brandt, Ulrike ⁱ   Sellami, Dalila ⁱ   Bruix, Jordi ^h  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^e Asan Medical Center   (South Korea)

^f Seoul National University Hospital   (South Korea)

^g HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^h INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

ⁱ NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Dose finding; Everolimus; Hepatocellular carcinoma; Mammalian target of rapamycin; Sorafenib

Indexed keywords

EVEROLIMUS; SORAFENIB;

ABDOMINAL PAIN; ADVANCED CANCER; ALOPECIA; ANEMIA; ARTICLE; ASCITES; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL ARTICLE; CONSTIPATION; COUGHING; CYTOPENIA; DECREASED APPETITE; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERBILIRUBINEMIA; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; INFECTION; LIVER CELL CARCINOMA; LIVER FUNCTION; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; ORAL MUCOSITIS; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; SKIN TOXICITY; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADVERSE EVENT; AE; ASPARTATE AMINOTRANSFERASE; AST; BARCELONA CLINIC LIVER CANCER; BCLC; BID; C(MAX); C(MIN); CI; CONFIDENCE INTERVAL; DCR; DISEASE CONTROL RATE; DLT; DOSE-FINDING; DOSE-LIMITING TOXICITY; EASTERN COOPERATIVE ONCOLOGY GROUP; ECOG; EVEROLIMUS; HBV; HCC; HEPATITIS B VIRUS; HEPATOCELLULAR CARCINOMA; MAMMALIAN TARGET OF RAPAMYCIN; MAXIMUM BLOOD CONCENTRATION; MAXIMUM TOLERATED DOSE; MINIMUM BLOOD CONCENTRATION; MTD; MTOR; ONCE DAILY; OS; OVERALL SURVIVAL; PDGFR; PLATELET-DERIVED GROWTH FACTOR RECEPTOR; QD; RCC; RDI; RECIST; RELATIVE DOSE INTENSITY; RENAL CELL CARCINOMA; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SD; SHAR; SORAFENIB; SORAFENIB HCC ASSESSMENT RANDOMIZED PROTOCOL; STANDARD DEVIATION; TIME TO PROGRESSION; TTP; TWICE DAILY; ULN; UPPER LIMIT OF NORMAL; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR; VEGFR;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; SIROLIMUS;

EID: 84887993101     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2013.07.029     Document Type: Article

References (29)

1. J.M. Llovet, A.M. Di Bisceglie, J. Bruix, B.S. Kramer, R. Lencioni, and A.X. Zhu Design and endpoints of clinical trials in hepatocellular carcinoma J Natl Cancer Inst 100 2008 698 711
2. S.M. Wilhelm, C. Carter, L. Tang, D. Wilkie, A. McNabola, and H. Rong BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res 64 2004 7099 7109
3. J.M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, and J.F. Blanc Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
4. A.L. Cheng, Y.K. Kang, Z. Chen, C.J. Tsao, S. Qin, and J.S. Kim Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial Lancet Oncol 10 2009 25 34
5. European Association for the Study of the Liver European Organisation for Research and Treatment of Cancer. EASL-EORTC Clinical Practice Guidelines: management of hepatocellular carcinoma J Hepatol 56 2012 908 943
6. J. Bruix, and M. Sherman Management of hepatocellular carcinoma: an update Hepatology 53 2011 1020 1022
7. J. LoPiccolo, G.M. Blumenthal, W.B. Bernstein, and P.A. Dennis Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations Drug Resist Update 11 2008 32 50
8. M.A. Bjornsti, and P.J. Houghton The TOR pathway: a target for cancer therapy Nat Rev Cancer 4 2004 335 348
9. A. Villanueva, D.Y. Chiang, P. Newell, J. Peix, S. Thung, and C. Alsinet Pivotal role of mTOR signaling in hepatocellular carcinoma Gastroenterology 135 2008 1972 1983
10. F. Sahin, R. Kannangai, O. Adegbola, J. Wang, G. Su, and M. Torbenson MTOR and P70 S6 kinase expression in primary liver neoplasms Clin Cancer Res 10 2004 8421 8425
11. W. Sieghart, T. Fuereder, K. Schmid, D. Cejka, J. Werzowa, and F. Wrba Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation Transplantation 83 2007 425 432
12. H. Huynh, K.H. Chow, K.C. Soo, H.C. Toh, S.P. Choo, and K.F. Foo RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma J Cell Mol Med 13 2009 1371 1380
13. A.C. Piguet, B. Saar, R. Hlushchuk, M.V. St-Pierre, P.M. McSheehy, and V. Radojevic Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma Mol Cancer Ther 10 2011 1007 1017
14. A.X. Zhu, T.A. Abrams, R. Miksad, L.S. Blaszkowsky, J.A. Meyerhardt, and H. Zheng Phase 1/2 study of everolimus in advanced hepatocellular carcinoma Cancer 117 2011 5094 5102
15. H.S. Shiah, C.Y. Chen, C.Y. Dai, C.F. Hsiao, Y.J. Lin, and W.C. Su Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma Aliment Pharmacol Ther 37 2013 62 73
16. P. Therasse, S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, and L. Rubinstein New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 2000 205 216
17. A. O'Donnell, S. Faivre, H.A. Burris III, D. Rea, V. Papadimitrakopoulou, and N. Shand Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors J Clin Oncol 26 2008 1588 1595
18. C. Tanaka, T. O'Reilly, J.M. Kovarik, N. Shand, K. Hazell, and I. Judson Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data J Clin Oncol 26 2008 1596 1602
19. J. Tabernero, F. Rojo, E. Calvo, H. Burris, I. Judson, and K. Hazell Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors J Clin Oncol 26 2008 1603 1610
20. R.J. Motzer, B. Escudier, S. Oudard, T.E. Hutson, C. Porta, and S. Bracarda Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors Cancer 116 2010 4256 4265
21. J.C. Yao, M.H. Shah, T. Ito, C.L. Bohas, E.M. Wolin, and E. Van Cutsem Everolimus for advanced pancreatic neuroendocrine tumors N Engl J Med 364 2011 514 523
22. B. Escudier, T. Eisen, W.M. Stadler, C. Szczylik, S. Oudard, and M. Staehler Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial J Clin Oncol 27 2009 3312 3318
23. J.M. Kovarik, H.D. Sabia, J. Figueiredo, H. Zimmermann, C. Reynolds, and S.C. Dilzer Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment Clin Pharmacol Ther 70 2001 425 430
24. J. Peveling-Oberhag, S. Zeuzem, W.P. Yong, T. Kunz, T. Paquet, and E. Bouillaud Effects of hepatic impairment on the pharmacokinetics of everolimus: a single-dose, open-label, parallel-group study Clin Ther 35 2013 215 225
25. A.L. Harzstark, E.J. Small, V.K. Weinberg, J. Sun, C.J. Ryan, and A.M. Lin A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma Cancer 117 2011 4194 4200
26. R.J. Amato, A.L. Flaherty, and M. Stepankiw Phase I trial of everolimus plus sorafenib for patients with advanced renal cell cancer Clin Genitourin Cancer 10 2012 26 31
27. C. Gomez-Martin, J. Bustamante, J.F. Castroagudin, M. Salcedo, E. Garralda, and M. Testillano Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation Liver Transpl 18 2012 45 52
28. R.K. Kelley, H.S. Nimeiri, P.N. Munster, M.T. Vergo, Y. Huang, and C.M. Li Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates Ann Oncol 2013 10.1093/annonc/mdt109
29. J. Bruix, J.L. Raoul, M. Sherman, V. Mazzaferro, L. Bolondi, and A. Craxi Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial J Hepatol 57 2012 821 829